+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Targeted PSMA Radionuclide Drug Conjugates Market by Radionuclide Type, Indication, Therapy Type, End User, Distribution Channel, Administration Route, Patient Age Group - Global Forecast to 2030- Product Image
Targeted PSMA Radionuclide Drug Conjugates Market by Radionuclide Type, Indication, Therapy Type, End User, Distribution Channel, Administration Route, Patient Age Group - Global Forecast to 2030- Product Image
Sale

Targeted PSMA Radionuclide Drug Conjugates Market by Radionuclide Type, Indication, Therapy Type, End User, Distribution Channel, Administration Route, Patient Age Group - Global Forecast to 2030

  • PDF Icon

    Report

  • 199 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6081575
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Unveiling the Rise of PSMA-Targeted Radionuclide Conjugates

The landscape of prostate-specific membrane antigen targeted radionuclide drug conjugates is experiencing an unprecedented surge in scientific innovation and clinical promise. Advances in radiochemistry and molecular targeting have converged to create a new class of precision therapeutics capable of delivering cytotoxic radiation directly to malignant prostate cancer cells. As research institutions and industry players accelerate development pipelines, these agents are transitioning from promising preclinical candidates to pivotal additions in treatment protocols.

This introduction sets the stage by highlighting the convergence of unmet medical need and technological breakthroughs. The growing prevalence of metastatic prostate cancer underscores the urgent demand for therapies with higher specificity and reduced systemic toxicity. At the same time, sophisticated imaging modalities are refining patient selection and treatment planning, further enhancing the therapeutic index of radionuclide drug conjugates. By examining the key drivers and contextualizing them within broader oncology trends, this executive summary provides a clear vista of the forces reshaping the field and the pathways to clinical and commercial success.

How Next-Generation Radionuclide Therapies Are Redefining Prostate Cancer Care

The field of PSMA-targeted radionuclide conjugates is being transformed by a series of paradigm shifts that promise to redefine therapeutic paradigms. First, the optimization of linker chemistry and chelators has dramatically improved the stability and delivery of actinium-225 labeled conjugates, overcoming historical challenges of off-target radiation. Concurrently, innovations in generator-produced gallium-68 isotopes have increased imaging accessibility, enabling real-time monitoring of therapeutic response.

Moreover, the integration of these agents into combination regimens represents a major departure from monotherapy. Early clinical studies suggest that pairing lutetium-177 conjugates with androgen receptor inhibitors can produce synergistic antitumor effects, opening avenues for treatment in both castration-resistant and castration-sensitive settings. Parallel advances in patient stratification using precision diagnostics are ensuring that therapeutic indices are maximized. Finally, the migration of research efforts from centralized academic centers to commercial manufacturing sites is accelerating scale-up and regulatory approval pathways. These transformative shifts collectively signal a maturation of the PSMA radionuclide conjugates ecosystem, positioning it for rapid expansion and deeper clinical impact.

Navigating the Ripple Effects of 2025 US Tariff Policy on Radiopharmaceuticals

The introduction of new tariff measures by the United States in 2025 has introduced complexity into the supply chain of radiopharmaceuticals, with broad implications for manufacturers, distributors, and end users. Tariffs applied to precursor chemicals and key components have raised input costs, particularly for isotopes requiring specialized production equipment and raw materials. This cost pressure is most pronounced in the production of high-energy alpha emitters, where supply scarcity and regulatory requirements already contribute to premium pricing.

In response, several developers have sought to diversify manufacturing footprints by forging partnerships with facilities in tariff-exempt jurisdictions, while others are investing in domestic production capacity to hedge against future policy shifts. Revisions to cost structures are being reflected in pricing negotiations with hospital systems and research institutes. At the same time, healthcare payers are scrutinizing value propositions more closely, demanding robust clinical data that demonstrate superior outcomes and cost-effectiveness. Navigating these tariff-driven headwinds will require agile supply chain strategies and proactive engagement with regulatory and reimbursement stakeholders.

Decoding Market Segments to Unlock Growth Opportunities

A nuanced comprehension of market segmentation is critical to identifying high-impact opportunities across the PSMA radionuclide conjugate landscape. When examining radionuclide types, Actinium-225 offers potent alpha emissions that yield profound tumoricidal effects, while Gallium-68 provides adaptable imaging capabilities to refine patient selection. Lutetium-177 bridges therapy and diagnostics through its beta emissions that enable both therapeutic and post-treatment imaging, and Technetium-99m continues to serve as a backbone isotope for established imaging protocols.

Evaluation by indication reveals that metastatic castration-resistant prostate cancer remains the most active clinical segment, driven by the urgent need for second-line therapies. Metastatic castration-sensitive prostate cancer is emerging as a fertile area for early intervention strategies, and non-metastatic prostate cancer programs are gaining traction through adjuvant and salvage treatment paradigms. In terms of therapy type, the contrast between combination regimens and monotherapy underscores the field’s shift toward multimodal approaches that enhance efficacy and delay resistance.

Insights into end users illuminate a balance between institutional adoption and specialized research efforts; clinics and hospitals are integrating radionuclide therapies into standard oncology workflows, while imaging centers leverage advanced scanners to support theranostic applications. Research institutes continue to drive innovation, particularly in next-generation conjugate design. Distribution channel analysis highlights the interplay between direct purchase and pharmacy-based models: direct purchase agreements streamline access for large cancer centers, hospital pharmacies manage in-house formulation and inventory control, and specialty pharmacies support home-based care models. Administration route is uniformly established as intravenous injection, underscoring the need for skilled infusion services. Finally, stratification by patient age group delineates adult populations aged 18 to 65 as primary beneficiaries of early-phase trials, with senior patients over 65 representing a growing cohort for expanded access and real-world studies.

Regional Dynamics Shaping Global Adoption of PSMA Radionuclide Therapies

Regional nuances are shaping the global trajectory of PSMA radionuclide therapies in distinct ways. In the Americas, robust clinical trial infrastructure and a mature reimbursement ecosystem have accelerated regulatory approvals and broadened patient access, particularly in the United States. Investment in domestic isotope production capacity is further strengthening the region’s leadership in both research and commercial supply.

Across Europe, the Middle East, and Africa, heterogeneous healthcare frameworks and varied regulatory landscapes create a tapestry of adoption rates. Western European markets are at the forefront of integrating novel theranostics into national health systems, while emerging Middle Eastern and African markets are catalyzing interest through targeted public-private partnerships that expand local manufacturing and clinical trial capabilities.

In the Asia-Pacific region, dynamic policy support and rising healthcare expenditure are propelling rapid adoption in countries such as Japan, South Korea, and Australia. Local collaborations between biotech firms and academic institutions are nurturing a pipeline of pipeline candidates and reinforcing the region’s position as a critical contributor to the global oncology ecosystem.

Competitive Landscape and Leading Innovators Driving Market Momentum

The competitive landscape of PSMA-targeted radionuclide drug conjugates is characterized by a mix of established radiopharmaceutical pioneers and agile biotech innovators. Leading development entities have leveraged decades of nuclear medicine expertise to advance late-stage assets targeting advanced prostate cancer, while nimble startups are differentiating through novel isotopic platforms and proprietary chelation technologies.

Strategic partnerships and licensing agreements are proliferating as companies seek to broaden their pipelines and mitigate development risk. Several major players have secured collaborations with academic medical centers to validate early-stage candidates and expedite translational research. Meanwhile, alliances with contract manufacturing organizations are enabling scalable production to meet anticipated commercial demand. Observers note that licensing deals incorporating milestone-based structures underscore confidence in regulatory approval trajectories and future revenue streams.

Strategic Imperatives for Industry Leaders in Radiopharmaceuticals

To capitalize on emerging opportunities in the PSMA radionuclide conjugate space, industry leaders must adopt a multi-faceted strategic playbook. First, expanding isotope supply resilience through vertical integration or strategic outsourcing will mitigate tariff and regulatory uncertainties. Second, prioritizing clinical programs that demonstrate clear differentiation in combination settings can position assets favorably with payers seeking value-based outcomes.

Third, forging cross-functional partnerships between diagnostic imaging and therapeutic development teams will optimize theranostic pathways and enhance patient segmentation. Fourth, cultivating real-world evidence through post-approval registries and expanded access initiatives will build robust safety and efficacy datasets, critical for broad payer reimbursement. Finally, embedding patient-centric service models, including coordinated infusion support and digital monitoring platforms, will strengthen market adoption and foster long-term brand loyalty.

Rigorous Research Framework Underpinning Market Insights

This report’s findings are grounded in a rigorous mixed-methods research framework. Primary research involved in-depth interviews with C-suite executives, clinical investigators, and regulatory affairs specialists, supplemented by field surveys among nuclear medicine practitioners to validate adoption trends. Secondary research encompassed a comprehensive review of peer-reviewed literature, patent filings, clinical trial registries, and public financial disclosures to triangulate technology advancements and competitive dynamics.

Quantitative analyses were conducted using detailed data sets from regulatory agencies, industry associations, and proprietary transaction databases. These data were normalized and segmented to ensure consistency and accuracy. Qualitative insights were synthesized through thematic coding, enabling the identification of strategic patterns and emerging growth vectors. Finally, all findings were subjected to multiple rounds of expert validation to confirm relevance and reliability.

Synthesizing Key Takeaways for Stakeholders

The confluence of technological innovation, clinical validation, and strategic collaboration positions PSMA radionuclide drug conjugates at the forefront of precision oncology. By understanding the drivers of market segmentation, navigating geopolitical and regulatory challenges, and aligning commercial strategies with patient-centric imperatives, stakeholders can unlock the full therapeutic and economic potential of this modality.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Radionuclide Type
    • Actinium-225
    • Gallium-68
    • Lutetium-177
    • Technetium-99m
  • Indication
    • Metastatic Castration-Resistant Prostate Cancer
    • Metastatic Castration-Sensitive Prostate Cancer
    • Non-Metastatic Prostate Cancer
  • Therapy Type
    • Combination Therapy
    • Monotherapy
  • End User
    • Clinic
    • Hospital
    • Imaging Center
    • Research Institute
  • Distribution Channel
    • Direct Purchase
    • Hospital Pharmacy
    • Specialty Pharmacy
  • Administration Route
    • Intravenous Injection
  • Patient Age Group
    • Adult 18-65
    • Senior 65+
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Novartis AG
  • Telix Pharmaceuticals Ltd
  • Point Biopharma Inc
  • Fusion Pharmaceuticals Inc
  • ITM Isotope Technologies Munich SE
  • Curium Pharma S.A.S
  • Lantheus Holdings Inc
  • Blue Earth Diagnostics Ltd
  • Bayer AG
  • RayzeBio Inc

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Targeted PSMA Radionuclide Drug Conjugates Market, by Radionuclide Type
8.1. Introduction
8.2. Actinium-225
8.3. Gallium-68
8.4. Lutetium-177
8.5. Technetium-99m
9. Targeted PSMA Radionuclide Drug Conjugates Market, by Indication
9.1. Introduction
9.2. Metastatic Castration-Resistant Prostate Cancer
9.3. Metastatic Castration-Sensitive Prostate Cancer
9.4. Non-Metastatic Prostate Cancer
10. Targeted PSMA Radionuclide Drug Conjugates Market, by Therapy Type
10.1. Introduction
10.2. Combination Therapy
10.3. Monotherapy
11. Targeted PSMA Radionuclide Drug Conjugates Market, by End User
11.1. Introduction
11.2. Clinic
11.3. Hospital
11.4. Imaging Center
11.5. Research Institute
12. Targeted PSMA Radionuclide Drug Conjugates Market, by Distribution Channel
12.1. Introduction
12.2. Direct Purchase
12.3. Hospital Pharmacy
12.4. Specialty Pharmacy
13. Targeted PSMA Radionuclide Drug Conjugates Market, by Administration Route
13.1. Introduction
13.2. Intravenous Injection
14. Targeted PSMA Radionuclide Drug Conjugates Market, by Patient Age Group
14.1. Introduction
14.2. Adult 18-65
14.3. Senior 65+
15. Americas Targeted PSMA Radionuclide Drug Conjugates Market
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. Argentina
16. Europe, Middle East & Africa Targeted PSMA Radionuclide Drug Conjugates Market
16.1. Introduction
16.2. United Kingdom
16.3. Germany
16.4. France
16.5. Russia
16.6. Italy
16.7. Spain
16.8. United Arab Emirates
16.9. Saudi Arabia
16.10. South Africa
16.11. Denmark
16.12. Netherlands
16.13. Qatar
16.14. Finland
16.15. Sweden
16.16. Nigeria
16.17. Egypt
16.18. Turkey
16.19. Israel
16.20. Norway
16.21. Poland
16.22. Switzerland
17. Asia-Pacific Targeted PSMA Radionuclide Drug Conjugates Market
17.1. Introduction
17.2. China
17.3. India
17.4. Japan
17.5. Australia
17.6. South Korea
17.7. Indonesia
17.8. Thailand
17.9. Philippines
17.10. Malaysia
17.11. Singapore
17.12. Vietnam
17.13. Taiwan
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. Novartis AG
18.3.2. Telix Pharmaceuticals Ltd
18.3.3. Point Biopharma Inc
18.3.4. Fusion Pharmaceuticals Inc
18.3.5. ITM Isotope Technologies Munich SE
18.3.6. Curium Pharma S.A.S
18.3.7. Lantheus Holdings Inc
18.3.8. Blue Earth Diagnostics Ltd
18.3.9. Bayer AG
18.3.10. RayzeBio Inc
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET MULTI-CURRENCY
FIGURE 2. TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET MULTI-LANGUAGE
FIGURE 3. TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2030 (%)
FIGURE 18. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 20. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. AMERICAS TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. AMERICAS TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. UNITED STATES TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 24. UNITED STATES TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ASIA-PACIFIC TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. ASIA-PACIFIC TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 30. TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY ACTINIUM-225, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY GALLIUM-68, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY LUTETIUM-177, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY TECHNETIUM-99M, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY NON-METASTATIC PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY CLINIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY IMAGING CENTER, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RESEARCH INSTITUTE, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DIRECT PURCHASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY INTRAVENOUS INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY ADULT 18-65, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY SENIOR 65+, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 40. UNITED STATES TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
TABLE 41. UNITED STATES TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 42. UNITED STATES TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 48. CANADA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
TABLE 49. CANADA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 50. CANADA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 51. CANADA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 52. CANADA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 53. CANADA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 54. CANADA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 55. MEXICO TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
TABLE 56. MEXICO TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 57. MEXICO TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 58. MEXICO TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 59. MEXICO TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 60. MEXICO TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 61. MEXICO TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 62. BRAZIL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
TABLE 63. BRAZIL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 64. BRAZIL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 65. BRAZIL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 66. BRAZIL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 67. BRAZIL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 68. BRAZIL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 69. ARGENTINA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
TABLE 70. ARGENTINA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 71. ARGENTINA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 72. ARGENTINA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 73. ARGENTINA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 74. ARGENTINA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 76. EUROPE, MIDDLE EAST & AFRICA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
TABLE 77. EUROPE, MIDDLE EAST & AFRICA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 78. EUROPE, MIDDLE EAST & AFRICA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 80. EUROPE, MIDDLE EAST & AFRICA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 82. EUROPE, MIDDLE EAST & AFRICA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 83. EUROPE, MIDDLE EAST & AFRICA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 84. UNITED KINGDOM TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
TABLE 85. UNITED KINGDOM TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 86. UNITED KINGDOM TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 87. UNITED KINGDOM TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 88. UNITED KINGDOM TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 89. UNITED KINGDOM TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 90. UNITED KINGDOM TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 91. GERMANY TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
TABLE 92. GERMANY TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 93. GERMANY TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 94. GERMANY TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 95. GERMANY TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 96. GERMANY TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 97. GERMANY TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 98. FRANCE TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
TABLE 99. FRANCE TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 100. FRANCE TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 101. FRANCE TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 102. FRANCE TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 103. FRANCE TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 104. FRANCE TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 105. RUSSIA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
TABLE 106. RUSSIA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 107. RUSSIA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 108. RUSSIA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 109. RUSSIA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 110. RUSSIA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 111. RUSSIA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 112. ITALY TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
TABLE 113. ITALY TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 114. ITALY TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 115. ITALY TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 116. ITALY TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 117. ITALY TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 118. ITALY TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 119. SPAIN TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
TABLE 120. SPAIN TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 121. SPAIN TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 122. SPAIN TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 123. SPAIN TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 124. SPAIN TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 125. SPAIN TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 126. UNITED ARAB EMIRATES TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
TABLE 127. UNITED ARAB EMIRATES TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 128. UNITED ARAB EMIRATES TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 129. UNITED ARAB EMIRATES TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 130. UNITED ARAB EMIRATES TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 131. UNITED ARAB EMIRATES TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 132. UNITED ARAB EMIRATES TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 133. SAUDI ARABIA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
TABLE 134. SAUDI ARABIA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 135. SAUDI ARABIA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 136. SAUDI ARABIA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 137. SAUDI ARABIA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 138. SAUDI ARABIA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 139. SAUDI ARABIA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 140. SOUTH AFRICA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
TABLE 141. SOUTH AFRICA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 142. SOUTH AFRICA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 143. SOUTH AFRICA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 144. SOUTH AFRICA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 145. SOUTH AFRICA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 146. SOUTH AFRICA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 147. DENMARK TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
TABLE 148. DENMARK TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 149. DENMARK TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 150. DENMARK TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 151. DENMARK TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 152. DENMARK TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 153. DENMARK TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 154. NETHERLANDS TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
TABLE 155. NETHERLANDS TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 156. NETHERLANDS TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 157. NETHERLANDS TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 158. NETHERLANDS TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 159. NETHERLANDS TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 160. NETHERLANDS TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 161. QATAR TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
TABLE 162. QATAR TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 163. QATAR TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 164. QATAR TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 165. QATAR TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 166. QATAR TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 167. QATAR TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 168. FINLAND TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
TABLE 169. FINLAND TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 170. FINLAND TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 171. FINLAND TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 172. FINLAND TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 173. FINLAND TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 174. FINLAND TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 175. SWEDEN TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
TABLE 176. SWEDEN TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 177. SWEDEN TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 178. SWEDEN TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 179. SWEDEN TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 180. SWEDEN TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 181. SWEDEN TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 182. NIGERIA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
TABLE 183. NIGERIA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 184. NIGERIA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 185. NIGERIA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 186. NIGERIA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 187. NIGERIA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 188. NIGERIA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 189. EGYPT TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
TABLE 190. EGYPT TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 191. EGYPT TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 192. EGYPT TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 193. EGYPT TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 194. EGYPT TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 195. EGYPT TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 196. TURKEY TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
TABLE 197. TURKEY TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 198. TURKEY TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 199. TURKEY TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 200. TURKEY TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 201. TURKEY TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 202. TURKEY TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 203. ISRAEL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
TABLE 204. ISRAEL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 205. ISRAEL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 206. ISRAEL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 207. ISRAEL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 208. ISRAEL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 209. ISRAEL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 210. NORWAY TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
TABLE 211. NORWAY TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 212. NORWAY TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 213. NORWAY TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 214. NORWAY TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 215. NORWAY TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 216. NORWAY TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 217. POLAND TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
TABLE 218. POLAND TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 219. POLAND TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 220. POLAND TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 221. POLAND TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 222. POLAND TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 223. POLAND TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 224. SWITZERLAND TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
TABLE 225. SWITZERLAND TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 226. SWITZERLAND TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 227. SWITZERLAND TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 228. SWITZERLAND TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 229. SWITZERLAND TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 230. SWITZERLAND TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 231. ASIA-PACIFIC TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
TABLE 232. ASIA-PACIFIC TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 233. ASIA-PACIFIC TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 234. ASIA-PACIFIC TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 235. ASIA-PACIFIC TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 236. ASIA-PACIFIC TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 237. ASIA-PACIFIC TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 238. ASIA-PACIFIC TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 239. CHINA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
TABLE 240. CHINA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 241. CHINA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 242. CHINA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 243. CHINA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 244. CHINA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 245. CHINA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 246. INDIA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
TABLE 247. INDIA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 248. INDIA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 249. INDIA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 250. INDIA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 251. INDIA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 252. INDIA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 253. JAPAN TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
TABLE 254. JAPAN TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 255. JAPAN TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 256. JAPAN TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 257. JAPAN TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 258. JAPAN TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 259. JAPAN TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 260. AUSTRALIA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
TABLE 261. AUSTRALIA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 262. AUSTRALIA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 263. AUSTRALIA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 264. AUSTRALIA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 265. AUSTRALIA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 266. AUSTRALIA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 267. SOUTH KOREA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2030 (USD MILLION)
TABLE 268. SOUTH KOREA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 269. SOUTH KOREA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 270. SOUTH KOREA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 271. SOUTH KOREA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 272. SOUTH KOREA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 273. SOUTH KOREA TARGETED PSMA RADIONUCLIDE DRUG CONJU

Companies Mentioned

The companies profiled in this Targeted PSMA Radionuclide Drug Conjugates market report include:
  • Novartis AG
  • Telix Pharmaceuticals Ltd
  • Point Biopharma Inc
  • Fusion Pharmaceuticals Inc
  • ITM Isotope Technologies Munich SE
  • Curium Pharma S.A.S
  • Lantheus Holdings Inc
  • Blue Earth Diagnostics Ltd
  • Bayer AG
  • RayzeBio Inc

Methodology

Loading
LOADING...

Related Reports

Targeted SSTR Radionuclide Drug Conjugates Market by Radiometal Type, Peptide Analog, Treatment Indication, Clinical Phase, End User, Distribution Channel - Global Forecast to 2030 - Product Image

Targeted SSTR Radionuclide Drug Conjugates Market by Radiometal Type, Peptide Analog, Treatment Indication, Clinical Phase, End User, Distribution Channel - Global Forecast to 2030

  • Report
  • 187 Pages
  • Global
From
Radiopharmaceutical Theranostics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029) - Product Image

Radiopharmaceutical Theranostics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029)

  • Report
  • 105 Pages
  • Global
From
Next Generation Drug Conjugates Market 2024 - Product Image

Next Generation Drug Conjugates Market 2024

  • Report
  • 175 Pages
  • Global
From
Next Generation Drug Conjugates Market Report 2025 - Product Image

Next Generation Drug Conjugates Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Prostate Cancer - Competitive landscape, 2024 - Product Image

Prostate Cancer - Competitive landscape, 2024

  • Clinical Trials
  • 450 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.